Dermatitis clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
open to eligible people ages 18-75
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
at UCLA
Our lead scientists for Dermatitis research studies include April W. Armstrong, MD, MPH.
Last updated: